Clinical Trial Update: Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for erlotinib in recurrent or metastatic skin squamous cell carcinoma; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Squamous Cell Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-06-11